Identification of risk factors for elevated transaminases in methotrexate users through an electronic health record

Arthritis Care and Research

Volumn 66, Issue 8, 2014, Pages 1159-1166

  Schmajuk, Gabriela ^a   Miao, Yinghui ^a   Yazdany, Jinoos ^a   Boscardin, W John ^a   Daikh, David I ^a   Steinman, Michael A ^a  

^a SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; FOLIC ACID; METHOTREXATE;

AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; ELECTRONIC MEDICAL RECORD; FEMALE; FOLLOW UP; HUMAN; HYPERTRANSAMINASEMIA; KIDNEY FUNCTION; LABORATORY TEST; LIVER FUNCTION TEST; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; OBESITY; OUTCOME ASSESSMENT; PREDICTION; PRESCRIPTION; PSORIATIC ARTHRITIS; RETROSPECTIVE STUDY; RHEUMATIC DISEASE; RISK FACTOR; TREATMENT DURATION; VETERAN; VITAMIN SUPPLEMENTATION;

AGED; AGED, 80 AND OVER; COHORT STUDIES; DRUG-INDUCED LIVER INJURY; ELECTRONIC HEALTH RECORDS; FEMALE; HUMANS; LIVER FUNCTION TESTS; MALE; METHOTREXATE; RETROSPECTIVE STUDIES; RISK FACTORS; TRANSAMINASES;

EID: 84905060587     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22294     Document Type: Article

References (31)

1. Sokka T,. Increases in use of methotrexate since the 1980s. Clin Exp Rheumatol 2010; 28: S13-20.
2. Davis SA, Feldman SR,. Combination therapy for psoriasis in the United States. J Drugs Dermatol 2013; 12: 546-50.
3. Visser K, van der Heijde DM,. Risk and management of liver toxicity during methotrexate treatment in rheumatoid and psoriatic arthritis: a systematic review of the literature. Clin Exp Rheumatol 2009; 27: 1017-25.
4. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheurmatoid arthritis. Arthritis Rheum 2008; 59; 762-84.
5. Kent PD, Luthra HS, Michet C Jr., Risk factors for methotrexate-induced abnormal laboratory monitoring results in patients with rheumatoid arthritis. J Rheumatol 2004; 31: 1727-31.
6. Sokolove J, Strand V, Greenberg JD, Curtis JR, Kavanaugh A, Kremer JM, et al. Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis. Ann Rheum Dis 2010; 69: 1612-7.
7. Crowson CS, Matteson EL, Myasoedova E, Michet CJ, Ernste FC, Warrington KJ, et al. The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis Rheum 2011; 63: 633-9.
8. Noel PH, Copeland LA, Perrin RA, Lancaster AE, Pugh MJ, Wang CP,. VHA Corporate Data Warehouse height and weight data: opportunities and challenges for health services research. J Rehabil Res Dev 2010; 47: 739-50.
9. Steinman MA, Lee SJ, Boscardin JW, Miao Y, Fung KZ, Moore KL, et al. Patterns of multimorbidity in elderly veterans. J Am Geriatr Soc 2012; 60: 1872-80.
10. Mendes FD, Levy C, Enders FB, Loftus EV Jr, Angulo P, Lindor KD,. Abnormal hepatic biochemistries in patients with inflammatory bowel disease. Am J Gastroenterol 2007; 102: 344-50.
11. Donnan PT, McLernon D, Steinke D, Ryder S, Roderick P, Sullivan FM, et al. Development of a decision support tool to facilitate primary care management of patients with abnormal liver function tests without clinically apparent liver disease [HTA03/38/02]: Abnormal Liver Function Investigations Evaluation (ALFIE). BMC Health Serv Res 2007; 167: 54.
12. Quam L, Ellis LB, Venus P, Clouse J, Taylor CG, Leatherman S,. Using claims data for epidemiologic research: the concordance of claims-based criteria with the medical record and patient survey for identifying a hypertensive population. Med Care 1993; 31: 498-507.
13. Borzecki AM, Wong AT, Hickey EC, Ash AS, Berlowitz DR,. Identifying hypertension-related comorbidities from administrative data: what's the optimal approach? Am J Med Qual 2004; 19: 201-6.
14. Deyo RA, Cherkin DC, Ciol MA,. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992; 45: 613-9.
15. World Health Organization. BMI classification. 2006. URL: http://apps.who.int/bmi/index.jsp?introPage=intro-3.html.
16. Navarro VJ, Senior JR,. Drug-related hepatotoxicity [review]. N Engl J Med 2006; 354: 731-9.
17. Harrell FE, Lee KL, Mark DB,. Tutorial in biostatistics. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996; 15: 361-87.
18. Kremer JM, Furst DE, Weinblatt ME, Blotner SD,. Significant changes in serum AST across hepatic histological biopsy grades: prospective analysis of 3 cohorts receiving methotrexate therapy for rheumatoid arthritis. J Rheumatol 1996; 23: 459-61.
19. U.S. Department of Health & Human Services. Doctors and hospitals' use of health IT more than doubles since 2012. 2013. URL: http://www.hhs.gov/ news/press/2013pres/05/20130522a.html.
20. Amarasingham R, Moore BJ, Tabak YP, Drazner MH, Clark CA, Zhang S, et al. An automated model to identify heart failure patients at risk for 30-day readmission or death using electronic medical record data. Med Care 2010; 48: 981-8.
21. Tabak YP, Sun X, Derby KG, Kurtz SG, Johannes RS,. Development and validation of a disease-specific risk adjustment system using automated clinical data. Health Serv Res 2010; 45: 1815-35.
22. Van Ede AE, Laan RF, Rood MJ, Huizinga TW, van de Laar MA, van Denderen CJ, et al. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight-week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2001; 44: 1515-24.
23. Rahmioglu N, Andrew T, Cherkas L, Surdulescu G, Swaminathan R, Spector T, et al. Epidemiology and genetic epidemiology of the liver function test proteins. PLoS One 2009; 4: e4435.
24. Neuschwander-Tetri BA, Clark JM, Bass NM, Van Natta ML, Unalp-, Arida A, Tonascia J, et al. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology 2010; 52: 913-24.
25. Kremer JM, Lee RG, Tolman KG,. Liver histology in rheumatoid arthritis patients receiving long-term methotrexate therapy: a prospective study with baseline and sequential biopsy samples. Arthritis Rheum 1989; 32: 121-7.
26. De Ledinghen V, Ratziu V, Causse X, Le Bail B, Capron D, Renou C, et al. Diagnostic and predictive factors of significant liver fibrosis and minimal lesions in patients with persistent unexplained elevated transaminases: a prospective multicenter study. J Hepatol 2006; 45: 592-9.
27. Cannon GW, Mikuls TR, Hayden CL, Ying J, Curtis JR, Reimold AM, et al. Merging Veterans Affairs Rheumatoid Arthritis registry and pharmacy data to assess methotrexate adherence and disease activity in clinical practice. Arthritis Care Res (Hoboken) 2011; 63: 1680-90.
28. Boers M, Nurmohamed MT, Doelman CJ, Lard LR, Verhoeven AC, Voskuyl AE, et al. Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann Rheum Dis 2003; 62: 842-5.
29. Yood MU, Campbell UB, Rothman KJ, Jick SS, Lang J, Wells KE, et al. Using prescription claims data for drugs available over-the-counter (OTC). Pharmacoepidemiol Drug Saf 2007; 16: 961-8.
30. Lane MA, McDonald JR, Zeringue AL, Caplan L, Curtis JR, Ranganathan P, et al. TNF-α antagonist use and risk of hospitalization for infection in a national cohort of veterans with rheumatoid arthritis. Medicine (Baltimore) 2011; 90: 139-45.
31. Willkens RF, Leonard PA, Clegg DO, Tolman KG, Ward JR, Marks CR, et al. Liver histology in patients receiving low dose pulse methotrexate for the treatment of rheumatoid arthritis. Ann Rheum Dis 1990; 49: 591-3.